Climb Bio's budoprutug achieves 38% immunologic remission rate at low dose in Phase 2 pMN trial

By Public Technologies
  • Climb Bio presented initial Phase 2 budoprutug results in primary membranous nephropathy at ASN Kidney Week 2026.
  • Low-dose treatment reduced disease-associated antibodies and produced immunologic remission, consistent with earlier findings.
  • Higher-dose treatment showed deeper B-cell depletion, supporting continued dose evaluation; additional trial data are expected in 2027.
  • Both evaluated doses were generally well tolerated, with no treatment-related serious adverse events or treatment discontinuations reported.
  • A separate minimal change disease case study presented at the meeting documented three-year steroid-free remission following budoprutug treatment.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Climb Bio Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610241930PRIMZONEFULLFEED9852595) on October 24, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.